Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

<![CDATA[HARMONi-6: Evaluating the Safety and Generalizability of Ivonescimab in NSCLC]]>

Ivonescimab is Now Being Studied in Europe in HARMONi-7 Trial – Lung Cancer Europe

Lung Cancer Europe shared a post on LinkedIn: “Ivonescimab was one of the most talked-about drugs in lung cancer at ASCO 2026, largely on th

ClinicalKey

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell #LungCancer (HARMONi-6): interim ove

Lung Cancer Patients on Drug From China’s Akeso Lived Longer

Promising news announced #ASCO26 for patients with #lungcancer. Dr. Roy Herbst comments on ivonescimab, noting the initial study results fro

PD-L1 High Advanced NSCLC: Is Immunotherapy Alone Always Enough?

For years, PD-L1 expression of 50% or higher has supported first-line PD-1 or PD-L1 inhibitor monotherapy for many patients with advanced no

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Phase 1 trial of ABBV-706 in 288 patients with advanced solid tumors reveals potential in SCLC: 240 on monotherapy, 124 with RR-SCLC. PMID:4